Biolegend, 575410, Recombinant Mouse IL-2 (carrier-free), 2μg

IL-2 is a potent lymphoid cell growth factor which exerts its biological activity primarily on T cells. Additionally, IL-2 has been found to stimulate growth and differentiation of B cells, NK cells, LAK cells, monocytes, and oligodendocytes.
2μg
Source: Mouse IL-2, amino acids Ala21-Gln169 (Accession # NM_008366) was expressed in E. coli.
Molecular Mass: The 150 amino acid N-terminal methionylated recombinant protein has a predicted molecular mass of 17,231 Da. The DTT-reduced protein and non-reduced protein migrates at approximately 18kDa by SDS-PAGE.
Purity: Purity is >98%, as determined by Coomassie stained SDS-PAGE.
Formulation: 0.22 µm filtered protein solution is in 5 mM Sodium Phosphate buffer, 5 mM citric acid, 350 mM NaCl, 1 mM TCEP, pH 4.0.
Endotoxin Level: Endotoxin level is <0.1 EU/µg (<0.01ng/µg) protein as determined by the LAL method.
Concentration: 10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling: Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
Activity: ED50 = 0.2 - 1.0 ng/ml, corresponding to a specific activity of 1.0 - 5.0 x106 units/mg, as determined by the dose dependent stimulation of CTLL2 cell proliferation. The specific activity of recombinant mouse IL-2 is approximately 9.07 x 104 IU/µg when compared against the Non WHO Reference Material for Murine Interleukin-2 (NIBSC code: 93/566) as determined by the dose dependent stimulation of CTLL2 cell proliferation. ED50 = 0.4 - 2.0 ng/ml, corresponding to a specific activity of 0.5 - 2.5 x106 units/mg, as determined by the dose dependent stimulation of HT-2 cell proliferation.For more information on specific activity, please visit the Recombinant Protein Unit Conversions page.
Application: Bioassay
Application Notes: BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at [email protected].
Additional Product Notes: Get a 50% discount on this product when purchased in our Activation Bundles. Restrictions apply. Learn more…
Application References(PubMed link indicates BioLegend citation): Detanico T, et al. 2011.J. Immunol. 187:82. PubMed Malu DT, et al. 2011. J. Immunol. 186:6271. PubMed Alcaide P, et al. 2012. J. Immunol. 188:1421. PubMed Williams JW, et al. 2013. Am J Physiol Lung Cell Mol Physiol. 305:693. PubMed
Product Citations: Aso K, et al. 2023. Nat Commun. 14:984. PubMed Liu HJ, et al. 2023. Nat Commun. 14:1214. PubMed Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed Adu-Berchie K, et al. 2023. Nat Commun. 14:3546. PubMed Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed Zhang Y, et al. 2022. Nat Med. 28:1421. PubMed Jou E, et al. 2022. Sci Immunol. 7:eabn0175. PubMed Balood M, et al. 2022. Nature. 611:405. PubMed Benakis C, et al. 2022. Elife. 11: . PubMed An HW, et al. 2022. Cell Rep. 41:111878. PubMed Chan L, et al. 2022. Cells. 12: . PubMed Liu Z, et al. 2023. Breast Cancer Res. 25:10. PubMed Yang J, et al. 2021. Cancer Immunol Res. 9:200. PubMed Han S, et al. 2022. Cancer Immunol Res. 10:437. PubMed Ye L, et al. 2022. Cell Metab. 34:595. PubMed Kania AK, et al. 2022. J Immunol. 208:1873. PubMed Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed Ruscetti M, et al. 2020. Cell. 181:424. PubMed Liu B, et al. 2019. Nat Commun. 10:354. PubMed Li Q, et al. 2022. Cell Rep. 40:111308. PubMed Sultan H, et al. 2018. Cancer Immunol Res. 6:617. PubMed Zhou Z, et al. 2021. Nat Biomed Eng. 5:1320. PubMed Wabitsch S, et al. 2021. STAR Protoc. 2:100517. PubMed Shi S, et al. 2020. Clin Cancer Res. 26:5990. PubMed Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed Gomez–Lopez N, et al. 2019. J Immunol. 203:1793. PubMed Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed Jacobsen JT, et al. 2021. Science. 373:. PubMed Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed Hrdinka M, et al. 2016. PLoS One. 11: 0162863. PubMed Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed Takushi SE, et al. 2020. Hum Gene Ther. 31:626. PubMed Morales-Mantilla DE, et al. 2022. Elife. 11:. PubMed Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed Chen X, et al. 2021. Cell Rep. 37:109991. PubMed Kania AK, et al. 2021. Immunohorizons. 5:918. PubMed Jacque E, et al. 2015. J Exp Med. 212:883. PubMed Han S, et al. 2020. Oncoimmunology. 9:1737368. PubMed Swan G, et al. 2021. Front Immunol. 12:641188. PubMed Hills LB, et al. 2021. J Immunol. 206:89. PubMed Frost JN, et al. 2021. Med (N Y). 2:164. PubMed Daneshmandi S, et al. 2021. Elife. 10:. PubMed Muthalagu N, et al. 2020. Cancer Discov. 1.022222222. PubMed Pasciuto E, et al. 2020. Cell. 182:625. PubMed Loo CS, et al. 2020. Immunity. 53:143. PubMed Zeis P, et al. 2020. Immunity. 53:775. PubMed Minns D, et al. 2021. Nat Commun. 12:1285. PubMed Xu H, et al. 2021. J Clin Invest. 131:. PubMed Jiang P, et al. 2018. Nat Med. 24:1550. PubMed Mohammadpour H, et al. 2020. JCI Insight. 5:00. PubMed Knox T, et al. 2019. Sci Rep. 9:6136. PubMed Detanico T, et al. 2011. J Immunol. 187:82. PubMed Roberts KJ, et al. 2021. Sci Rep. 11:19422. PubMed Zhou S, et al. 2021. Adv Funct Mater. 31:. PubMed Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed Bao K, et al. 2016. J Immunol. 197(11):4371-4381. PubMed Walker JA, et al. 2020. Immunity. 51(1):104-118. PubMed Yue T, et al. 2022. Cell Death Differ. 29:218. PubMed Frech M, et al. 2020. MethodsX. 7:101054. PubMed Choi HS, et al. 2020. Cell Rep. 30:2989. PubMed Patterson DG, et al. 2021. J Immunol. 207:1798. PubMed
Structure: Cytokine
Bioactivity: Proliferation of T lymphocytes, B cells, anti-inflammatory, hematopoiesis, tumor surveillance
Cell Sources: T cells
Cell Targets: T cells, B cells, NK cells, LAK cells, monocytes, macrophages, oligodendrocytes
Receptors: High affinity heterotrimer of IL-2Rα/β/γ, intermediate affinity homodimer IL-2Rα (CD25; p55; Tac) and heterodimer IL-2Rβ (CD122)/γ; γ-subunit (CD132) in common with IL-4R, IL-7R, IL-13R, IL-15R
Cell Type: Embryonic Stem Cells, Hematopoietic stem and progenitors
Biology Area: Cell Biology, Stem Cells
Molecular Family: Cytokines/Chemokines
Regulation: Upregulated by NFAT; downregulated by TCF-8, CIF (colostrum inhibitory factor)
Gene ID: 16183
UniProt: View information about IL-2 on UniProt.org
Regulatory Status: RUO
Other Names: Interleukin-2, T cell growth factor (TCGF), Eosinophil differentiation factor (EDF), Killer cell helper factor (KHF), Macrophage-activating factor for cytotoxicity I (MAF-C I), Thymocyte differentiation factor (TDF)
Q: Why choose BioLegend recombinant proteins?
A: • Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
     • Greater than 95% Purity or higher, tested on every lot of product.
     • 100% Satisfaction Guarantee for quality performance, stability, and consistency.
     • Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
     • Bulk and customization available. Contact us.
     • Learn more about our Recombinant Proteins.
Q: How does the activity of your recombinant proteins compare to competitors?
A: We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!
Q: What is the specific activity or ED50 of my recombinant protein?
A: The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.
Q: Have your recombinants been tested for stability?
A: Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.
Q: Does specific activity of a recombinant protein vary between lots?
A: Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.
Q: How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?
A: Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)